Listed

Amneal Pharmaceuticals, Inc.: Form 10-Q for the period ended Mar 31, 2023

Filed with the SEC on May 9, 2023 and accepted by EDGAR at May 9, 2023, 16:53 ET.

Share

Management's discussion and analysis

As filed, 30,333 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Amneal Pharmaceuticals, Inc. (the “Company”, “we,” “us,” or “our”) is a global pharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines, including complex generics and specialty branded pharmaceuticals. We operate principally in the United States (the “U.S.”), India, and Ireland, and sell to wholesalers, distributors, hospitals, chain pharmacies and individual pharmacies, either directly or indirectly. We are a holding company, whose principal assets are common units (“Amneal Common Units”) of Amneal Pharmaceuticals, LLC (“Amneal”).

The Company held 50.2% of Amneal Common Units and the group, together with their affiliates and certain assignees, who owned Amneal when it was a private company held the remaining 49.8% as of March 31, 2023. The Company is Amneal’s sole managing member, having the sole voting power to make all of Amneal’s business decisions and control its management. Therefore, the Company consolidates the financial statements of Amneal and its subsidiaries. The Company records non-controlling interests for the portion of Amneal’s economic interests that it does not hold.

The following discussion and analysis contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those set forth under Item 1A. Risk Factors in our 2022 Annual Report on Form 10-K and under the heading Cautionary Note Regarding Forward-Looking Statements included elsewhere in this Quarterly Report on Form 10-Q.

The following discussion and analysis for the three months ended March 31, 2023 should also be read in conjunction with the consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and with our audited consolidated financial statements for the year ended December 31, 2022 included in our 2022 Annual Report on Form 10-K.

Overview

We have three reportable segments: Generics, Specialty, and AvKARE.

Generics

Our Generics segment includes approximately 260 product families covering an extensive range of dosage forms and delivery systems, including both immediate and extended release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, ophthalmics, films, transdermal patches and topicals. We focus on developing products with substantial barriers-to-entry resulting from complex drug formulations or manufacturing, or legal or regulatory challenges. Generic products, particularly in the U.S., generally contribute most significantly to revenues and gross margins at the time of their launch, and even more so in periods of market exclusivity, or in periods of limited generic competition. As such, the timing of new product introductions can have a significant impact on the Company’s financial results. The entrance into the market of additional competition generally has a negative impact on the volume and/or pricing of the affected products. Additionally, pricing is determined by market place dynamics and is often affected by factors outside of the Company’s control.

Specialty

Our Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products, with a focus on products addressing CNS disorders, including Parkinson’s disease, and endocrine disorders. Our portfolio of products includes Rytary®, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. In addition to Rytary®, our promoted Specialty portfolio also includes Unithroid® (levothyroxine sodium), for the treatment of hypothyroidism, which is sold under a license and distribution agreement with Jerome Stevens Pharmaceuticals, Inc., and Lyvispah® (baclofen), a unique dissolvable granule formulation used to treat muscle stiffness, spasms and pain from multiple sclerosis.

Our Specialty products are marketed through skilled specialty sales and marketing teams, who call on neurologists, movement disorder specialists, endocrinologists and primary care physicians in key markets throughout the U.S. Our Specialty segment also has a number of product candidates that are in varying stages of development.

For Specialty products, the majority of the product’s commercial value is usually realized during the period in which the product has market exclusivity. In the U.S., when market exclusivity expires and generic versions of a product are approved and marketed, there can often be very substantial and rapid declines in the branded product’s sales.

AvKARE

Our AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies. AvKARE is a re-packager of bottle and unit dose pharmaceuticals under the registered names of AvKARE and AvPAK, which service the Department of Defense and Department of Veteran Affairs as well as institutional customers. AvKARE is also a wholesale distributor of pharmaceuticals, over the counter products and medical supplies to institutional customers which are located throughout the U.S. focused primarily on offering 340b-qualified entities products to provide consistency in care and pricing.

The Pharmaceutical Industry

The pharmaceutical industry is highly competitive and highly regulated. As a result, we face a number of industry-specific factors and challenges, which can significantly impact our results. For a more detailed explanation of our business and its risks, refer to our 2022 Annual Report on Form 10-K, as supplemented by Part II, Item 1A “Risk Factors” of our subsequent Quarterly Reports on Form 10-Q.

Inflation

While it is difficult to accurately measure the impact of inflation, we estimate our business will experience an increase in costs due to inflation of approximately $15.0 million for the year ending December 31, 2023, excluding the impact of rising interest rates. However, rising inflationary pressures due to higher input costs, including higher material, transportation, labor and other costs, could exceed our expectations, which would further adversely impact our operating results in future periods.

Uncertainties in Financial Markets

In March 2023, certain U.S. and international government banking regulators took steps to intervene in the operations of certain financial institutions due to liquidity concerns, which caused general heightened uncertainties in financial markets. While these events have not had a material direct impact on our operations, if further liquidity and financial stability concerns arise with respect to banks and financial institutions, either nationally or in specific regions, our ability to access cash or enter into new financing arrangements on favorable terms, or at all, may be threatened, which could have a material adverse effect on our business, financial condition and results of operations.

Results of Operations

Consolidated Results

The following table sets forth our summarized, consolidated results of operations for the three months ended March 31, 2023 and 2022 (in thousands):

Three Months Ended March 31, 2023 2022 Increase (Decrease) $%
Net revenue $557,540 $497,633 $59,907 12.0%
Cost of goods sold 379,354 323,062 56,292 17.4%
Gross profit 178,186 174,571 3,615 2.1%
Selling, general and administrative 102,096 98,665 3,431 3.5%
Research and development 38,690 52,798 (14,108) (26.7)%
Intellectual property legal development expenses 1,644 764 880 115.2%
Acquisition, transaction-related and integration expenses — 434 (434) nm
Restructuring and other charges 510 731 (221) (30.2)%
Change in fair value of contingent consideration 2,457 200 2,257 nm
Credit related to legal matters, net (436) (2,326) 1,890 (81.3)%
Other operating income (1,224) — (1,224) nm
Operating income 34,449 23,305 11,144 47.8%
Total other expense, net (43,875) (33,226) (10,649) 32.1%
Loss before income taxes (9,426) (9,921) 495 (5.0)%
Provision for (benefit from) income taxes 668 (3,461) 4,129 (119.3)%
Net loss $(10,094) $(6,460) $(3,634) 56.3%

nm - not meaningful

Net Revenue

Net revenue for the three months ended March 31, 2023 increased 12.0% from the prior year period primarily due to:

  • Growth in our Generics segment of $26.1 million primarily due to favorable timing of new products launched in 2023 and 2022 that contributed net revenue growth of $30.5 million and volume growth, partially offset by continued price erosion. Net revenue for the three months ended March 31, 2023 included a non-recurring customer order of $21.0 million related to 2022 new product launches.
  • An increase in our Specialty segment net revenue of $6.6 million primarily driven by increases in net revenue of 38.5% and 14.1% in our promoted products Unithroid® and Rytary®, respectively, resulting from continued strong prescription growth.
  • An increase in our AvKARE segment net revenue of $27.3 million primarily driven by growth in our distribution channel.

Cost of Goods Sold and Gross Profit

Cost of goods sold increased 17.4% for the three months ended March 31, 2023 as compared to the prior year period. The increase in cost of goods sold was primarily due to increased Generics and AvKARE volume and an increase in the inventory provision. Cost of goods sold for the three months ended March 31, 2023 included $11.0 million associated with the non-recurring customer order in our Generics segment discussed above.

Gross profit as a percentage of net revenue decreased to 32.0% for the three months ended March 31, 2023 from 35.1% in the prior year period primarily as a result of the factors noted above.

Selling, General, and Administrative

Selling, general, and administrative (“SG&A”) expenses for the three months ended March 31, 2023 increased 3.5% from the prior year period primarily due to increases in employee compensation and costs associated with our biosimilar launches, partially offset by a decrease of $5.0 million associated with a regulatory approval in the prior year period.

Research and Development

Research and development (“R&D”) expenses for the three months ended March 31, 2023 decreased 26.7% compared to the prior year period primarily due to a decrease in in-licensing and upfront milestone payments of $5.2 million, reduced project spend of $3.7 million and operating efficiencies in our infrastructure.

Intellectual Property Legal Development Expense

Intellectual property legal development expenses include, but are not limited to, costs associated with formulation assessments, patent challenge opinions and strategy, and litigation expenses to defend our intellectual property. Intellectual property legal development expenses for the three months ended March 31, 2023 and 2022 were $1.6 million and $0.8 million, respectively. Expenses may vary based on the number of individual cases and corresponding litigation outstanding in a particular period.

Change in Fair Value of Contingent Consideration

Refer to Note 17. Fair Value Measurements for information about the estimation of our contingent consideration liabilities. The $2.3 million increase in the change in fair value of contingent consideration for the three months ended March 31, 2023 as compared to the prior year period was primarily driven by a decrease in our cost of debt and the passage of time.

Credits Related to Legal Matters, Net

For the three months ended March 31, 2023, we recorded a net credit of $0.4 million for a litigation settlement gain, partially offset by charges for legal proceedings. For the three months ended March 31, 2022, we recorded a net credit of $2.3 million for an insurance recovery of $4.0 million, partially offset by charges for legal proceedings.

Other Operating Income

Other operating income for the three months ended March 31, 2023 was comprised of income earned from the India Production Linked Incentive Scheme for the Pharmaceutical Sector. Refer to Note 6. Government Grants for additional information.

Total Other Expense, Net

Total other expense, net for the three months ended March 31, 2023 increased 32.1% compared to the prior year period. This increase was primarily driven by a $16.0 million increase in interest expense as a result of higher rates on our variable rate debt and increased amounts outstanding on our revolving credit facility, partially offset by $3.9 million in period over period foreign exchange gains related to the Indian rupee and the Euro.

Provision For Income Taxes

For the three months ended March 31, 2023 and 2022, our provision for (benefit from) income taxes and effective tax rates were $0.7 million and (7.1)% and $(3.5) million and 34.9%, respectively. The period-over-period change was primarily related to a change in the jurisdictional mix of income and a discrete benefit resulting from of the completion of an Internal Revenue Service examination and Joint Committee review of the 2012-2018 federal income tax returns, which enabled the Company to recognize previously unrecognized tax benefits in the three months ended March 31, 2022.

Generics

The following table sets forth results of operations for our Generics segment for the three months ended March 31, 2023 and 2022 (in thousands):

Three Months Ended March 31, 2023 2022 Increase (Decrease) $%
Net revenue $343,806 $317,747 $26,059 8.2%
Cost of goods sold 230,551 199,030 31,521 15.8%
Gross profit 113,255 118,717 (5,462) (4.6)%
Selling, general and administrative 27,600 27,593 7 nm
Research and development 32,359 43,221 (10,862) (25.1)%
Intellectual property legal development expenses 1,624 772 852 110.4%
Restructuring and other charges 99 206 (107) (51.9)%
(Credit) charges related to legal matters, net (2,444) 1,674 (4,118) (246.0)%
Other operating income (1,224) — (1,224) nm
Operating income $55,241 $45,251 $9,990 22.1%

nm - not meaningful

Net Revenue

Generics net revenue for the three months ended March 31, 2023 increased 8.2% compared to the prior year period primarily due to favorable timing of new products launched in 2023 and 2022 that contributed revenue growth of $30.5 million and volume growth, partially offset by continued price erosion. Net revenue for the three months ended March 31, 2023 included a non-recurring customer order of $21.0 million related to 2022 new product launches.

Cost of Goods Sold and Gross Profit

Generics cost of goods sold for the three months ended March 31, 2023 increased 15.8% compared to the prior year period primarily due to the costs associated with increased sales volume and an increased inventory provision. Cost of goods sold for the three months ended March 31, 2023 included $11.0 million associated with the non-recurring customer order discussed above.

Generics gross profit as a percentage of net revenue decreased to 32.9% for the three months ended March 31, 2023 from 37.4% in the prior year period primarily as a result of the factors noted above.

Selling, General, and Administrative

Generics SG&A expense for the three months ended March 31, 2023 was flat compared to the prior year period as increases in employee compensation and costs associated with our biosimilar launches were offset by a decrease of $5.0 million associated with a regulatory approval in the prior year period.

Research and Development

Generics R&D expenses for the three months ended March 31, 2023 decreased 25.1% compared to the prior year period primarily due to a decrease in in-licensing and upfront milestone payments of $2.7 million, reduced project spend of $2.4 million and operating efficiencies in our infrastructure.

Intellectual Property Legal Development Expenses

Intellectual property legal development expenses include, but are not limited to, costs associated with formulation assessments, patent challenge opinions and strategy, and litigation expenses to defend our intellectual property. Intellectual property legal development expenses for the three months ended March 31, 2023 and 2022 were $1.6 million and $0.8 million, respectively. Expenses may vary based on the number of individual cases and corresponding litigation outstanding in a particular period.

(Credit) Charges Related to Legal Matters, Net

For the three months ended March 31, 2023, a litigation settlement gain was partially offset by charges for legal proceedings. For the three months ended March 31, 2022, we recorded charges of $1.7 million for legal proceedings.

Other Operating Income

Other operating income for the three months periods ended March 31, 2023 was comprised of income earned from the India Production Linked Incentive Scheme for the Pharmaceutical Sector. Refer to Note 6. Government Grants for additional information.

Specialty

The following table sets forth results of operations for our Specialty segment for the three months ended March 31, 2023 and 2022 (in thousands):

Three Months Ended March 31, 2023 2022 Increase (Decrease) $%
Net revenue $91,678 $85,086 $6,592 7.7%
Cost of goods sold 43,191 43,853 (662) (1.5)%
Gross profit 48,487 41,233 7,254 17.6%
Selling, general and administrative 22,379 24,400 (2,021) (8.3)%
Research and development 6,331 9,577 (3,246) (33.9)%
Intellectual property legal development expenses (credit) 20 (8) 28 nm
Change in fair value of contingent consideration 2,457 200 2,257 nm
Operating income $17,300 $7,064 $10,236 144.9%

nm - not meaningful

Net Revenue

Specialty net revenue for the three months ended March 31, 2023 increased 7.7% compared to the prior year period, primarily driven by increases in net revenue of 38.5% and 14.1% in our promoted products Unithroid® and Rytary®, respectively, resulting from continued strong prescription growth.

Cost of Goods Sold and Gross Profit

Specialty cost of goods sold for the three months ended March 31, 2023 decreased 1.5% compared to the prior year period. Specialty gross profit as a percentage of net revenue increased to 52.9% for the three months ended March 31, 2023 from 48.5% in the prior year period, primarily due to the increase in net revenues and favorable product mix.

Selling, General, and Administrative

Specialty SG&A expense for the three months ended March 31, 2023 decreased 8.3% compared to the prior year period primarily due to a decrease in third party marketing spend for our promoted products.

Research and Development

Specialty R&D expenses for the three months ended March 31, 2023 decreased 33.9% compared to the prior year period primarily due to a decrease in in-licensing and upfront milestone payments of $2.5 million.

Change in Fair Value of Contingent Consideration

Refer to Note 17. Fair Value Measurements for information about the estimation of our contingent consideration liabilities. The $2.3 million increase in the change in fair value of contingent consideration for the three months ended March 31, 2023 as compared to the prior year period was primarily driven by a decrease in our cost of debt and the passage of time.

AvKARE

The following table sets forth results of operations for our AvKARE segment for the three months ended March 31, 2023 and 2022 (in thousands):

Three Months Ended March 31, 2023 2022 Increase (Decrease) $%
Net revenue $122,056 $94,800 $27,256 28.8%
Cost of goods sold 105,612 80,179 25,433 31.7%
Gross profit 16,444 14,621 1,823 12.5%
Selling, general and administrative 12,940 13,410 (470) (3.5)%
Operating income $3,504 $1,211 $2,293 189.3%

Net Revenue

AvKARE net revenue for the three months ended March 31, 2023 increased 28.8% compared to the prior year period primarily driven by growth in our distribution channel.

Cost of Goods Sold and Gross Profit

AvKARE cost of goods sold for the three months ended March 31, 2023 increased 31.7% compared to the prior year period, and gross profit as a percentage of net revenue decreased to 13.5% for the three months ended March 31, 2023 from 15.4% in the prior year period primarily due to the increase in sales through our lower margin distribution channel.

Liquidity and Capital Resources

Our primary source of liquidity is cash generated from operations, available cash on hand and borrowings under debt financing arrangements, including $245.9 million of available capacity on our New Revolving Credit Facility, as defined in Note 16. Debt in our 2022 Annual Report on Form 10-K, as of March 31, 2023. Refer to Note 16. Debt in our 2022 Annual Report on Form 10-K for additional information on our debt. We believe these sources are sufficient to fund our planned operations, meet our interest and contractual obligations, including acquisitions, and provide sufficient liquidity over the next 12 months from the date of filing of this Form 10-Q. However, our ability to satisfy our working capital requirements and debt obligations will depend upon economic conditions, our ability to negotiate and maintain satisfactory terms under our borrowing and debt facilities in the future, and demand for our products, which are factors that may be out of our control.

We estimate that we will invest approximately $50.0 million to $60.0 million during 2023 for capital expenditures to support and grow our existing operations, primarily related to investments in manufacturing equipment, information technology and facilities.

During the three months ended March 31, 2023, we prepaid $22.8 million of principal outstanding on the Rondo Term Loan. Over the next 12 months, we expect to make substantial payments, including a $50.0 million payment associated with the Opana ER® antitrust litigation settlement agreements, monthly interest and quarterly principal amounts due for our debt instruments, including our Term Loan and Rondo Term Loan, as well as contractual payments for leased premises. Refer to Note 16. Debt and Note 18. Leases in our 2022 Annual Report on Form 10-K for additional information on our indebtedness and leases, respectively.

We are party to a tax receivable agreement (“TRA”) that requires us to make cash payments to the Members other than the Company, in respect of certain tax benefits that we may realize or may be deemed to realize as a result of sales or exchanges of Amneal Common Units by the Members. The timing and amount of any payments under the TRA will also vary, depending upon a number of factors including the timing and number of Amneal Common Units sold or exchanged for our class A common stock, the price of our class A common stock on the date of sale or exchange, the timing and amount of our taxable income, and the tax rate in effect at the time of realization of our taxable income. The tax receivable agreement also requires that we make an accelerated payment to the Members equal to the present value of all future payments due under the agreement upon certain change of control and similar transactions. Further sales or exchanges occurring subsequent to March 31, 2023 could result in future Amneal tax deductions and obligations to pay 85% of such benefits to the holders of Amneal Common Units. These obligations could be incremental to and substantially larger than the approximate $202.7 million contingent liability as of March 31, 2023 (refer to Note 7. Income Taxes). As a result of the foregoing, our obligations under the tax receivable agreement could have a substantial negative impact on our liquidity. For further details, refer to Item 1A. Risk Factors in our 2022 Annual Report on Form 10-K.

In addition, pursuant to the limited liability operating agreement of Amneal, as amended, in connection with any tax period, we will be required to make distributions to Amneal’s members, on a pro rata basis in proportion to the number of Amneal Common Units held by each member, of cash until each member (other than Amneal) has received an amount at least equal to its assumed tax liability and Amneal has received an amount sufficient to enable it to timely satisfy all of its U.S. federal, state and local and non-U.S. tax liabilities, and meet its obligations pursuant to the TRA. During the three months ended March 31, 2023 and 2022, we made cash tax distributions of $18.04 million and $2.53 million (net), respectively, to the Members. During April 2023, we made cash tax distributions of $8.77 million to the Members.

In 2020, we acquired a 65.1% controlling interest in both AvKARE Inc., a Tennessee corporation, now a limited liability company (“AvKARE, LLC”), and Dixon-Shane, LLC d/b/a R&S Northeast LLC, a Kentucky limited liability company (“R&S”). The sellers of AvKARE, LLC and R&S (the “AvKARE Sellers”) hold the remaining 34.9% interest in the holding company that directly owns the acquired companies (“Rondo”). We attribute 34.9% of the net income or loss associated with Rondo to redeemable non-controlling interests. During the three months ended March 31, 2023 and 2022, we made cash tax distributions of $0.18 million and $0.63 million, respectively, to the AvKARE Sellers. During April 2023, we made cash tax distributions of $2.78 million to the AvKARE Sellers.

As of March 31, 2023, our cash and cash equivalents consist of cash on deposit and highly liquid investments. A portion of our cash flows are derived outside the U.S. As a result, we are subject to market risk associated with changes in foreign exchange rates. We maintain cash balances at both U.S. based and foreign country based commercial banks. At various times during the year, our cash balances held in the U.S. may exceed amounts that are insured by the Federal Deposit Insurance Corporation (FDIC). We make our investments in accordance with our investment policy. The primary objectives of our investment policy are liquidity and safety of principal.

Cash Flows

The following table sets forth our summarized, consolidated cash flows for the three months ended March 31, 2023 and 2022 (in thousands):

Cash provided by (used in): Three Months Ended March 31, 2023 2022 Increase (Decrease) $%
Operating activities $139,712 $120,343 $19,369 16.1%
Investing activities (11,737) (97,395) 85,658 (87.9)%
Financing activities (12,900) (61,570) 48,670 (79.0)%
Effect of exchange rate changes on cash 767 (1,572) 2,339 (148.8)%
Net increase (decrease) in cash, cash equivalents, and restricted cash $115,842 $(40,194) $156,036 (388.2)%

Cash Flows from Operating Activities

Net cash provided by operating activities was $139.7 million for the three months ended March 31, 2023 as compared to $120.3 million for the prior year period. The increase in operating cash flows from the prior year period was primarily driven by increased period-over-period collections of outstanding accounts receivable due to timing of sales in the quarter ended December 31, 2022, receipt of a $21.4 million upfront payment associated with the Orion Agreement and a lower net loss adjusted for non-cash items, partially offset by an $83.9 million payment related to the Opana ER® antitrust litigation settlement agreements in January 2023.

Cash Flows from Investing Activities

Net cash used in investing activities for the three months ended March 31, 2023 was $11.7 million as compared to $97.4 million for the prior year period. The decrease in net cash used in investing activities from the prior year period was primarily due to cash paid to acquire certain assets comprising a business from entities affiliated with Saol International Limited during the prior year period.

Cash Flows from Financing Activities

Net cash used in financing activities was $12.9 million for the three months ended March 31, 2023 as compared to $61.6 million for the prior year period. The decrease in net cash used in financing activities from the prior year period was primarily due to a $44.0 million payment for deferred consideration associated with the acquisition of Kashiv Specialty Pharmaceuticals, LLC in the prior year period and net borrowings under the New Revolving Credit Facility of $40.0 million, partially offset by a $22.8 million prepayment of principal on the Rondo Term Loan and a $15.1 million increase in tax distributions to non-controlling interests. Refer to Note 16. Debt in our 2022 Annual Report on Form 10-K for details of our debt, including defined terms.

Commitments and Contractual Obligations

The contractual obligations of the Company are set forth in Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in the Company’s 2022 Annual Report on Form 10-K. As of March 31, 2023, there have been no material changes to the disclosure presented in our 2022 Annual Report on Form 10-K.

Off-Balance Sheet Arrangements

We did not have any off-balance sheet arrangements as of March 31, 2023.

Critical Accounting Policies and Estimates

For a discussion of the Company’s critical accounting policies and estimates, see Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations in our 2022 Annual Report on Form 10-K. There have been no material changes to the disclosures presented in our 2022 Annual Report on Form 10-K.

Recently Issued Accounting Standards

Recently issued accounting standards are discussed in Note 2. Summary of Significant Accounting Policies.

Market risk

As filed, 198 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

There has not been any material change in our assessment of market risk as set forth in Item 7A. Quantitative and Qualitative Disclosures About Market Risk, in our 2022 Annual Report on Form 10-K.

Controls and procedures

As filed, 2,877 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) that are designed to ensure information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Co-Chief Executive Officers and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management, with the participation of our Co-Chief Executive Officers and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based upon that evaluation, our Co-Chief Executive Officers and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of March 31, 2023.

Changes in Internal Control over Financial Reporting

During the quarter ended March 31, 2023, there were no changes in our internal control over financial reporting which materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on the Effectiveness of Controls

Management, including our Co-Chief Executive Officers and Chief Financial Officer, does not expect that our disclosure controls and procedures or our system of internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed or operated, can provide only reasonable, but not absolute, assurance that the objectives of the system of internal control are met. The design of our control system reflects the fact that there are resource constraints, and that the benefits of such control system must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control failures and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the intentional acts of individuals, by collusion of two or more people, or by management override of the controls. The design of any system of controls is also based in part on certain assumptions about the likelihood of future events, and there can be no assurance that the design of any particular control will always succeed in achieving its objective under all potential future conditions.

Risk factors

As filed, 134 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

There have been no material changes to the disclosures presented in our 2022 Annual Report on Form 10-K under Item 1A. Risk Factors.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2023-01-01 to 2023-03-31$557.5mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2023-01-01 to 2023-03-31$379.4mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2023-01-01 to 2023-03-31$178.2mus-gaap:GrossProfit
Research and development3 months2023-01-01 to 2023-03-31$38.7mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2023-01-01 to 2023-03-31$102.1mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2023-01-01 to 2023-03-31$34.4mus-gaap:OperatingIncomeLoss
Income tax3 months2023-01-01 to 2023-03-31$668.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2023-01-01 to 2023-03-31−$15.6mus-gaap:NetIncomeLoss
Diluted EPS3 months2023-01-01 to 2023-03-31−$0.05us-gaap:EarningsPerShareDiluted
Basic EPS3 months2023-01-01 to 2023-03-31−$0.05us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2023-01-01 to 2023-03-31152,109,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2023-01-01 to 2023-03-31$139.7mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2023-01-01 to 2023-03-31$9.7mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2023-03-31$144.7mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2023-03-31$1.31bnus-gaap:AssetsCurrent
Total assetsAt period end2023-03-31$3.63bnus-gaap:Assets
Current liabilitiesAt period end2023-03-31$703.7mus-gaap:LiabilitiesCurrent
Long-term debtAt period end2023-03-31$2.56bnus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2023-03-31$30.0mus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2023-03-31$294.4mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001723128-23-000020. Last ingested by Listed: Nov 10, 2026, 02:45 ET. Listed shows no prices and gives no investment advice.